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Since  vaccination  against  human  papillomavirus  (HPV)  became  available,  awareness  of  HPV  has  dramati-
cally  increased.  Implementation  of a vaccine  program  varies  internationally  yet no  studies  have  explored
the  inﬂuence  this  has  on  the public’s  knowledge  of  HPV.  The  present  study  aimed  to  explore  differences
in  awareness  of  HPV  and  HPV  knowledge  across  three  countries:  The  US,  UK  and  Australia.
Participants  (n  =  2409)  completed  a validated  measure  of HPV  knowledge  as  part  of an  online  survey.
There  were  higher  levels  of  HPV  awareness  among  men  and  women  in  the  US  than  the  UK  and  Australia.
Being  male  and  having  a lower  educational  level  was  associated  with  lower  HPV  awareness  in  all  three
countries.  Awareness  of  HPV  vaccine  was  higher  in  women  from  the  US  than  the  UK  and  Australia.  Women
in the US  scored  signiﬁcantly  higher  on general  HPV  knowledge  (on  a 15-item  scale)  than  women  in the
UK and  Australia,  but  there  were  no  between  country  differences  in  HPV  vaccine  knowledge  (on  a 6-item
scale). When  asked  about  country-speciﬁc  vaccine  availability,  participants  in the  US  were  less  able  tonternational
easure
identify  the correct  answers  than  participants  in  the  UK  and  Australia.  More  than  half  of  participants  did
not know:  HPV  can  cause  genital  warts;  most  sexually  active  people  will  get  HPV  at  some  point  in  their
life; or  HPV  doesn’t  usually  need treatment.
Pharmaceutical  advertising  campaigns  could  explain  why  awareness  of  HPV  and  HPV  vaccine  is higher
in the US  and  this  has helped  to  get some  important  messages  across.  Signiﬁcant  gaps  in HPV  knowledge
remain  across  all  three  countries.. Introduction
Infection with genital high-risk types of human papillomavirus
HPV) can have a number of serious consequences, most notably
ervical cancer. HPV types 16 and 18 contribute to around 74% of
ervical cancers [1] as well as to cancers of the anus, penis, vulva,
agina, mouth and oropharynx [2].  HPV types 6 and 11 cause almost
ll cases of genital warts [3].  Prevention of HPV would therefore
educe the incidence of a number of cancers as well as genital warts,
long with the morbidity, mortality and costs associated with these
iseases.
Two prophylactic vaccinations against HPV have been licenced
y the US Food and Drug Administration (FDA) for use with young
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emiology and Public Health, UCL, Gower Street, London WC1E 6BT, UK.
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women (Gardasil®, produced by Merck and approved in 2006, and
Cervarix®, produced by GlaxoSmithKline and approved in 2009).
Both vaccines protect against HPV types 16 and 18 and Gardasil®
also protects against types 6 and 11. Australia was the ﬁrst country
to implement a nationwide publicly-funded vaccination program
(in 2007), offering HPV vaccination for free to all girls aged 12–13
years through school-based programmes, with catch-up programs
targeting young women  aged 14–18 in schools and 18–26 years in
the community. Over the last ﬁve years most developed countries
have made HPV vaccination available for young women, although
the choice of vaccine, the cohorts it is offered to, the way  it is admin-
istered and the cost to the consumer varies. A report published in
April 2009 reviewed HPV vaccination availability across Europe [4].
At that time nine out of forty countries offered free vaccination, the
UK was  the only country to offer a school-based program and in
most Eastern European countries HPV vaccination was only avail-
able privately. In the UK, all girls age 12–13 are offered the vaccine
in a free, school-based program that was  launched in 2008. A catch-
up campaign for girls up to age 18 years was  run in the ﬁrst two
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Box 1: The context of HPV vaccination in the US,  UK
and Australia
US UK Australia
Vaccination
used
Gardasil/Cervarix Cervarix (Gardasil
from 2012)
Gardasil
Date of
introduction
2006–2007
(Gardasil) and 2009
(Cervarix), varies
by state
September 2008 July 2007
Eligibility 9–26 years All girls in school
year 8 (12–13 years)
along with a
catch-up campaign
for girls up to 18
years old.
Girls aged 12–13
years (school year
7–8 depending on
area) along with an
initial catch-up
campaign for
women aged 14–26.
Also available to
boys age 12–13
years with a catch
up program for
boys aged 14 years
from 2013.
Administration Predominantly
through health care
providers
Predominantly
through schools
Predominantly
through schools
Cost The cost of the
vaccine is covered
by most insurance
providers or is free
for those that
qualify for the
vaccines for
children program
Free to all eligible
girls
Free to all eligible
girls (and boys
from 2013)
Information
available
- Adverts from
pharmaceutical
companies
-  Information
provided by
schools (varies by
state)
- Additional
information
available on
various websites,
including CDC
- Department of
Health funded
website, TV and
radio campaign at
the time the
vaccine was
launched
- Leaﬂets
distributed through
schools with the
invitation letter
-  Additional
information
available on
various websites
Commonwealth
Department of
Health and Aging
funded website, TV
and radio
campaign at the
time the vaccine
was launched
- Leaﬂets
distributed through
schools with the
invitation letter
-  Additional
information
available on64 L.A.V. Marlow et al. / V
ears of the program. In the US implementation of HPV vaccination
aries by state but is mostly available through physicians’ ofﬁces
nd medical clinics [5]. The cost of vaccination is covered by most
rivate insurance companies and through the federal Vaccines for
hildren program (for those who are publically insured, uninsured,
r underinsured). Debate in the US about making HPV vaccination
 requirement for middle school entry is on-going [6].
Knowledge and understanding of HPV infection and vaccination
re important factors in insuring informed decisions. However HPV
s complicated and does not ﬁt neatly with lay understanding of
ancer or other sexually transmitted infections (STIs). The infection
tself is very common, yet its serious consequences (i.e. cancers) are
are. It usually clears spontaneously or becomes undetectable, yet
his is not always the case. Risk of HPV can be dramatically reduced
sing condoms, yet they are not as protective against HPV as they
re against other STIs.
Introduction of HPV vaccination has been accompanied with
arying levels of publicity in the media and materials produced by
harities, government organisations, and pharmaceutical compa-
ies, distributed via visual and print media and the internet. Before
he introduction of the HPV vaccine, population-representative sur-
eys suggested that around 25%–50% of women had heard of HPV
7–9]. Other studies with speciﬁc sub-groups of the population sug-
ested a wide range of HPV awareness, with levels as low as 13%
mong adolescents [10] and as high as 93% in clinic-based sam-
les [11]. Studies suggested that awareness of HPV was  highest
mong women and those from high socio-economic backgrounds
7,8,12,13]. Since the introduction of the HPV vaccination aware-
ess of HPV seems to have increased, particularly among parents
14]. In particular, the sexually transmitted nature of the virus and
ts potential to cause cervical cancer are the most widely known
acts [15,16].
In 2008, a systematic review of all HPV knowledge studies con-
luded that there were no differences between countries [12], but
ecause only small numbers of studies were included no statistical
nalyses were run. In addition this review only included studies
arried out before HPV vaccination was introduced. Comparing
nowledge across countries is of particular interest in the case of
PV vaccination. Despite many similarities between the US, UK and
ustralia there were distinct differences in the way  HPV vaccina-
ion was introduced (see Box 1). Most notably, the introduction
f Gardasil in the US was accompanied by a million dollar adver-
ising campaign launched by Merck, to encourage young women
o be vaccinated. In the UK and Australia direct-to-consumer (DTC)
dvertising is not permitted, limiting TV advertising to government
ponsored campaigns which were on a much smaller scale. Other
dvertising in the UK and Australia was more targeted, focussing
n information leaﬂets aimed at those eligible for the vaccine.
We explored awareness and knowledge of HPV and HPV vacci-
ation among men  and women in the US, UK and Australia, using
 validated measure [17]. The study aimed to (i) explore differ-
nces in awareness of HPV and knowledge of HPV between the US,
K and Australia, (ii) consider whether socio-demographic predic-
ors of knowledge are similar across the three countries, and (iii)
dentify gaps in knowledge.
. Methods
.1. Participants
Participants were recruited through international online panels
anaged by Survey Sampling International (SSI). Panel members
re individuals who have signed up to take part in online research
tudies in return for small rewards (e.g. airmiles). At the time of
he present survey there were 236,088 (UK), 1,790,981 (US) andvarious websites
80,249 (Australian) members on the panels associated with those
three countries. Samples of participants were invited to take part
in the present study. The samples were structured to reﬂect the
demographic characteristics of the country in terms of gender, age
and location. Participants were sent a generic recruitment email
(Subject: We  want your opinion; email text: exciting new sur-
vey opportunity! We  appreciate your participation. Please click
below). When participants clicked on the link in the email they were
directed to an online survey titled ‘what do you know about HPV?’
The target sample was  800 participants from each country in the
age range 18–70 years. Quotas were set to ensure equal numbers
of men/women completed the survey. Participants were invited in
waves until the recruitment target was met.
2.2. Measures
Participants were given information about the purpose of the
study, reassurance of conﬁdentially and anonymity, and contact
details for researchers in each country. Participants then reported
their age, gender and country of residence and if eligible to take part
(i.e. their quota was not full) were asked “before today, had you ever
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Table 1
Sample characteristics.
US (n = 813) UK (n = 799) Australia (n = 797) Signiﬁcance
Age [mean (standard deviation)] 46.03 (15.38) 41.84 (14.85) 48.07 (15.05) F = 35.35, p < 0.001
Sex  [n (%)]
Male 398 (49.0) 395 (49.4) 396 (49.7) NS
Female 415 (51.0) 404 (50.6) 401 (50.3)
Relationship status [n (%)]
Single 293 (36.0) 281 (35.2) 220 (27.6) 2(6) = 50.15, < 0.001
Dating  59 (7.3) 83 (10.4) 67 (8.4)
Cohabiting 55 (6.8) 114 (14.3) 101 (12.7)
Married 406 (49.9) 321 (40.2) 409 (51.3)
Ethnicitya [n (%)]
Majority 680 (83.7) 666 (83.4) 605 (75.9) 2(2) = 20.29, < 0.001
Minority 132 (16.3) 133 (16.6) 192 (24.1)
Educationc [n (%)]
High 297 (36.5) 273 (34.3) 177 (22.2) 2(4) = 85.15, < 001
Medium 307 (37.8) 312 (39.2) 272 (34.1)
Low  209 (25.7) 211 (26.5) 348 (43.7)
Have a daughter 9–17 years [n(%)] 101 (12.4) 115 (14.4) 107 (13.4) NS
Had  HPV vaccineb [n(%)] 44 (10.6) 29 (7.2) 50 (12.5) 2(2) = 6.40, 0.041
NS: Not signiﬁcant i.e. p > 0.05.
a Majority in US = White non-Hispanic, UK = White British, AUS = Australian.
b Women  only.
c Education was coded as follows:
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edium: Some college/Associate degree (US), Vocational/A-levels/other qualiﬁcati
ow:  High school, CED or below (US), no formal education/GCSEs (UK), No formal e
eard of human papillomavirus (HPV)?” Those who had heard of
PV responded to 15-items assessing knowledge of HPV (includ-
ng transmission, consequences, risk factors) and the item “before
oday, had you ever heard of HPV vaccination?”. Those who had
eard of HPV vaccination responded to 7-items about the proce-
ure and protection offered by HPV vaccines and 6-items (5-items
or Australian participants) about the availability of HPV vaccina-
ion in their country. These policy items differed between countries
o take account of the different healthcare systems through which
he vaccine is offered (see Supplementary material). The response
ptions for all items were true/false/don’t know. Development and
alidation of the HPV knowledge items is described elsewhere
17]. Participants also reported demographics, whether they had
eceived HPV vaccination and if they had a daughter in the HPV
accination age range (9–17 years).
.3. Analyses
Chi-square tests were used to evaluate whether there were
ifferences in HPV awareness, HPV vaccine awareness and indi-
idual item-level knowledge across the three countries. ANOVAs
ere used to explore differences in mean knowledge scores across
ountries, and post hoc Tukey’s tests were used to establish
here signiﬁcant differences lay. Because there were differences
n some demographic characteristics between the three countries
see Table 1) we ran a series of additional analyses controlling
or these potential confounders (age, relationship status, ethnicity,
ducation and, for women, vaccine status). As adjusting for these
ariables did not alter the signiﬁcance of any ﬁndings and in the
nterest of parsimony, we have reported the unadjusted results.
ogistic regression analyses were used to explore demographic cor-
elates of HPV awareness within each country. Only variables that
ere signiﬁcant at the p < 0.05 level in univariate analyses were
ntered into the multivariate models. Analyses of the individual
nowledge items used Bonferroni corrections to adjust for mul-
iple testing. Signiﬁcance values of p < 0.003 were used for general
PV knowledge items and p < 0.007 for HPV vaccine items. Analyses
ere carried out using SPSS version 18.ersity education (AUS).
gree (UK), Vocational qualiﬁcation (AUS).
on/high school (AUS).
3. Results
Overall 12,259 men  and women were directed to the HPV
knowledge survey, of whom 3959 were eligible and invited to take
part. The survey was completed by 2442 participants (62% response
rate). Thirty-three cases were excluded due to anomalies in the
data, leaving 2409 cases for analyses: USA (n = 813), UK (n = 799)
and Australia (n = 797) (see Fig. 1). Sample characteristics are shown
in Table 1.
3.1. Awareness of HPV and general HPV knowledge
Overall 61.1% had heard of HPV before. In each of the three
countries women were more likely to have heard of HPV than men
(in the US unadjusted OR = 4.09, CI: 2.86–5.85; in the UK unad-
justed OR = 2.49, CI: 1.87–3.31; in Australia unadjusted OR  = 3.61,
CI: 2.68–4.85). There were higher levels of HPV awareness among
men  in the US (64%) than the UK (39%) and Australia (41%). Among
women, the highest awareness was in the US  (88%), lowest aware-
ness in the UK (62%) with Australia falling between the two  (72%)
[see Table 2].
For all three countries lower educational level was associated
with lower HPV awareness in men  and women [see Table 3]. In
addition, relationship status was associated with awareness in US
men, age was associated with awareness in UK men  and having a
daughter aged 9–17 years old was associated with awareness in
Australian men. For women, age was associated with awareness
in the US, having a daughter aged 9–17 years was  associated with
awareness in the UK and having had the vaccine was associated
with awareness in Australia [see Table 3].
Those who  had heard of HPV completed a 15-item HPV knowl-
edge scale and the mean number of items correctly identiﬁed as
true or false was  8.44 (SD = 3.92). In the US and the UK women
had higher mean knowledge scores than men (US: 9.22 compared
with 8.00, t(615) = 3.57, p < 0.001; UK: 8.53 compared with 7.74,
t(402) = 1.99, p = 0.048). Overall the mean HPV  knowledge score for
men  was  7.97 (SD = 4.20) with no signiﬁcant differences across the
three countries. For women the mean HPV knowledge score was
766 L.A.V. Marlow et al. / Vaccine 31 (2013) 763– 769
Table 2
Awareness and mean knowledge scores by country.
Men  Women
US UK Aus. 2 or F (p-value) US UK Aus. 2 or F (p-value)
Heard of HPV (%) 63.6a 39.2b 41.4b 57.65 (<0.001) 87.7a 61.6b 71.8c 73.37 (<0.001)
Heard  of HPV vaccine (%) 69.2 67.1 71.3 0.68 (0.714) 91.8a 80.7b 81.3b 20.09 (<0.001)
HPV  knowledge score (mean) 8.00 7.74 8.16 0.40 (0.672) 9.22a 8.53ab 8.31b 5.48 (0.004)
HPV  vaccine knowledge score (mean) 3.62 3.59 3.94 1.52 (0.220) 4.15 4.08 4.15 0.15 (.865)
HPV  vaccine availability score (mean) 2.17 3.36 2.36 N/A 2.21 4.08 2.60 N/A
a,b,c Different superscript letters represent signiﬁcant differences at p < 0.05 in post hoc Tukey’s tests or 2 × 2 chi-square analyses.
Where superscript letters are the same, between-group differences are not signiﬁcant.
Directed to  survey  (n= 12,259)
Completed (n= 2,44 2)
Total  sa mpl e (n=2,409)
US=81 3
UK=79 9
Australi a=797
Eligible to t ake part (n =3,959)
Scre ened out (n=71 7)*
Quota full (n=7 ,583 )
Excluded (n=33 )**
Dropped out (n=1,51 7)
Hea rd of HPV
(n=1 ,473 )
Heard of HPV
vacc ine (n=1,165)
* Refers to those  who  we re outs ide the age range 18 -70  years
** Due to incons istenc ies  in the da ta which  led us  to  believe the survey  was not being  comp let ed
pro perly
Fig. 1. Recruitment overview.
Table 3
Socio-demographic correlates of HPV awareness for each country for men  and women (multivariate models).
Men  Women
USA (n = 398) UK (n = 393) AUS (n = 395) USA (n = 415) UK (n = 403) AUS (n = 401)
Educationa
High 1.00 1.00 1.00 1.00 1.00 1.00
Medium 0.66 [0.41–1.07] 0.50 [0.31–0.80]** 0.59 [0.35–1.00] 0.30 [0.12–0.77]* 0.37 [0.22–0.62]*** 0.89 [0.44–1.82]
Low  0.49 [0.28–0.85]* 0.34 [0.19–0.59]*** 0.29 [0.17–0.49]*** 0.18 [0.07–0.46]*** 0.22 [0.13–0.98]*** 0.51 [0.26–0.98]*
Relationship
Married 1.00 – – 1.00 –
In  a relationship/cohabiting 2.01 [0.96–4.21] – – 4.17 [0.95–18.25] –
Single 0.62 [0.40–0.97]* – – 1.00 [0.53–1.91] –
Age –  0.98 [0.97–0.99]** – 0.98 [0.96–1.00]* –
Have  a daughter 9–17 years – – 2.29 [1.22–4.31]* – 2.23 [1.18–4.24]**
Had HPV vaccine N/A N/A N/A – – 0.39 [0.17–0.91]*
Note: Variables that were not signiﬁcantly associated with HPV awareness in univariate logistic regression analyses were not included in the multivariate model.
a Education was coded as follows: High: College graduate/graduate school (US), Degree/post-graduate degree (UK), Any university education (AUS), Medium: some
college/Associate degree (US), Vocational/A-levels/other qualiﬁcation < degree (UK), Vocational qualiﬁcation (AUS), Low: high school, CED or below (US), no formal educa-
tion/GCSEs (UK), No formal education/high school (AUS).
* p < 0.05.
** p < 0.01.
*** p < 0.001.
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Table 4
Individual item level differences in general HPV knowledge and HPV vaccination knowledge by country.
Men  Women
US UK AUS 2 US UK AUS 2
General HPV knowledge in those aware of HPV (men, n = 572; women, n = 901)
HPV can cause cervical cancer 76.9 79.4 77.4 NS 92.6a 86.3b 85.1b 10.39 (0.006)
A  person could have HPV for many years without knowing it 65.6 67.1 65.9 NS 82.7 78.3 79.2 NS
Having many sexual partners increases the risk of getting HPV 70.0 71.6 74.4 NS 76.1 74.7 72.9 NS
HPV  is very rare (F) 64.0 54.2 69.5 NS 76.9a 67.1b 78.1a 10.38 (0.006)
HPV  can be passed on during sexual intercourse 66.8 70.3 71.3 NS 74.2 67.1 66.7 NS
HPV  always has visible signs or symptoms (F) 58.5 56.8 55.5 NS 78.0 71.1 76.7 NS
Using condoms reduces the risk of getting HPV 55.7 60.0 68.9 NS 60.7 68.3 61.6 NS
HPV  can cause HIV/Aids (F) 52.6 52.3 53.7 NS 60.4 65.9 58.0 NS
HPV  can be passed on by genital skin-to-skin contact 56.1 52.9 60.4 NS 51.9 51.0 54.9 NS
Men  cannot get HPV (F) 55.7 50.3 49.4 NS 61.0a 55.0b 45.8c 14.93 (.001)
Having  sex at an early age increases the risk of getting HPV 51.4 45.2 48.2 NS 62.1a 58.2a 43.8b 23.17 (<0.001)
There  are many types of HPV 53.4 48.4 49.4 NS 57.7a 45.8b 46.2b 11.88 (0.003)
HPV  can cause genital warts 45.8 48.4 56.1 NS 49.5 48.2 51.4 NS
HPV  can be cured with antibiotics (F) 40.3 35.5 33.5 NS 54.4 48.2 45.1 NS
Most  sexually active people will get HPV at some point in their lives 29.6 21.9 23.8 NS 31.9a 24.9ab 19.4b 13.11 (0.001)
HPV  usually doesn’t need any treatment 9.9 12.3 12.3 NS 9.3 8.4 4.5 NS
HPV  vaccine knowledge in those aware of HPV vaccine (men, n = 396; women, n = 769)
Girls who have had an HPV vaccine do not need a Pap test when they are older (F) 74.3 61.5 77.8 NS 88.0 82.6 92.3 NS
One  of the HPV vaccines offers protection against genital warts 76.6 69.2 71.8 NS 84.4 82.1 80.3 NS
HPV  vaccines offer protection against all sexually transmitted infections (F) 76.6 69.2 71.8 NS 84.4 82.1 80.3 NS
Someone who  has an HPV vaccine cannot develop cervical cancer (F) 74.3 60.6 66.7 NS 80.8a 71.6b 66.2b 16.02 (<0.001)
HPV  vaccines offer protection against most cervical cancers 44.0 53.8 62.4 NS 53.9 61.2 62.8 NS
The  HPV vaccine requires three doses 29.7 39.4 40.2 NS 47.9a 39.3a 59.0b 17.04 (<0.001)
HPV  vaccines are most effective if given to people who  have never had sex 37.1 49.0 41.0 NS 41.0a 50.7b 35.5a 10.54 (0.005)
Note 1: Making Bonferroni corrections for each gender means overall 2 were considered signiﬁcant at p < 0.003 for general HPV knowledge items and at p < 0.007 for HPV
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,b,c Different superscript letters represent signiﬁcant differences in 2 × 2 chi-square
 = correct answer is ‘false.’
.74 (SD = 3.70), with women in the US scoring signiﬁcantly higher
han women in Australia (9.22 compared to 8.31, p = 0.005) and
lightly higher than women in the UK (8.53, p = 0.058 – bordering
n signiﬁcant). Looking at item level differences between the three
ountries showed no differences for men, however more women
n the US responded correctly to a number of items than women in
he UK and/or Australia. These items related to cervical cancer as a
onsequence of HPV, the prevalence of HPV, that there are different
ypes of HPV, that men  can get HPV and that having sex at an early
ge increases the risk of getting HPV (see Table 4).
.2. Awareness of HPV vaccination and HPV vaccination
nowledge
Of the 1473 participants who had heard of HPV, 79.1% had heard
f HPV vaccination. In each country, women were more likely to
e aware of HPV vaccination than men  (in the US OR = 4.96, CI:
.14–7.85; in the UK OR = 2.05, CI: 1.30–3.25; in Australia OR = 1.74,
I: 1.11–2.73). Awareness of HPV vaccination was  similar for men
n all three countries. Among women awareness was  higher in the
S (92%) than in the UK and Australia (both 81%) [Table 2]. Very
ew of the socio-demographic factors showed associations with
wareness of HPV vaccine. Lower educational level was associated
ith lower HPV vaccine awareness in US men  and having a daugh-
er aged 9–17 years was associated with higher awareness in UK
omen and Australian men.
Participants completed a 7-item scale assessing their knowl-
dge of HPV vaccination. Mean scores were 3.71 (SD = 1.73) for
en  and 4.13 (SD = 1.59) for women. Women  had higher HPV vac-
ination knowledge scores than men  in the US (4.15 compared to
.62; t(507) = 3.36, p = 0.001) and the UK (4.08 compared to 3.59,
(303) = 2.48, p = 0.014), but not in Australia. There were no differ-
nces in mean HPV vaccine knowledge scores between the three
ountries for men  or women. Table 4 shows item level differences
etween the three countries. While there were no between countryses at p < 0.05.
differences for men, there were for women. Women  in the US were
more aware that HPV vaccine does not protect against all cervi-
cal cancers; women in Australia were more likely to know that the
vaccine requires 3 doses; and women in the UK were more likely
to know that HPV vaccine is most effective if given to people who
have never had sex.
Additional items assessed knowledge of HPV vaccination avail-
ability, using different items for each of the three countries (6-items
in the US and UK, 5-items in Australia; see Supplementary mate-
rial). Mean scores on these scales were higher for women  than men
in the UK (4.08 compared to 3.36, t(303) = 3.96, p < 0.001), but there
were no gender differences in the US and Australia. Although not
directly comparable we  have presented the proportion of men  and
women correctly answering items on different themes in Fig. 2. Par-
ticipants in the US were less able to identify the correct answer to
items about the cost of the vaccine, the setting where it is offered,
whether it is available for males, whether it is available to older
women and the protection offered by the vaccine.
4. Discussion
Women  had higher awareness of HPV than men and were
more likely to have heard of the vaccine, which is consistent
with previous ﬁndings [12,15] and is not surprising given that
current strategies mostly involve offering and marketing the vac-
cine to women  only. Education was  signiﬁcantly associated with
awareness of HPV, which is also consistent with previous research
[7,8,13]. Other demographic variables associated with awareness
varied by country and gender.
Awareness of HPV in general and HPV vaccination was  higher
in the US than in Australia and the UK. One possible explana-
tion for this is the abundance of publicity about HPV produced by
the pharmaceutical industry with drug company adverts being the
most common source for having heard of HPV in the US [18,19].
There are no studies in the UK or Australia asking about sources
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aFig. 2. The percentage of men  and women  in the US, UK and
f information on HPV but common sources of information on
omen’s health and cervical cancer prevention in the UK and
ustralia include health professionals (particularly the GP), talk-
ng to friends and reading leaﬂets [20,21]. In addition controversy
urrounding mandating HPV vaccination has been widely reported
n the US media [22].
Most participants who had heard of HPV knew its association
ith cervical cancer (77–79% of men  and 85–93% of women) and
hat HPV is sexually transmitted (70–74% of men  and 73–76% of
omen). This is consistent with other studies [15,16] and suggests
hat information campaigns have successfully raised awareness of
ome aspects of HPV knowledge as pre-vaccine introduction fewer
espondents were reported to know these facts [7,23].  Knowledge
f other aspects regarding HPV and HPV vaccination could still be
reatly improved, for example more than half of those who had
eard of HPV did not know: HPV can cause genital warts; most sex-
ally active people will get HPV at some point in their life; or HPV
oesn’t usually need treatment and more than half of those who
ad heard of HPV vaccine did not know that it requires three doses
nd is most effective if given to people who have never had sex. In
ddition more than a third of participants responded incorrectly to
tems about the ability for condoms to reduce the risk of HPV and
bout men  getting HPV as well as women. Interestingly, there were
o inter-country differences in correctly identifying the statement
PV can cause genital warts as true, despite the fact that both the
S and Australia offer Gardasil and at the time of data collection the
K only offered Cervarix. Confusion about whether HPV is related
o HIV/AIDS was also common, although this item has been found
o correlate poorly with other aspects of HPV knowledge, so should
erhaps be interpreted with caution [17].
Some interesting paradoxes emerged from the data, for example
hat fact that most women were aware that vaccination does not
ule out the need for future cervical screening (83–92% across the
hree countries) and yet 19–34% of women were uninformed about
he fact that it is possible to develop cervical cancer despite receiv-
ng the vaccine. The discrepancy was particularly marked among
ustralian women (see Table 4), and is consistent with ﬁndings
rom a survey in Victoria [24]. The ﬁnding suggests that messages
bout the need for future screening may  need to be underpinnedralia correctly responding to HPV vaccine availability items.
with clearer information about the limitations of the vaccine–i.e.
that it does not prevent all cervical cancers.
US women were more likely to know about the link between
HPV and cervical cancer, that HPV is common and that there are
different types of HPV than women in the UK and Australia. These
were the three messages covered in the Gardasil campaigns ‘tell
someone’ (about HPV) and ‘one less’ (with the message that by
being vaccinated, you could be one woman less affected by cer-
vical cancer). The campaigns included TV advertising in the US and
our ﬁndings suggest that these advertisements did more than sim-
ply raise awareness. However, when asked about the availability of
the vaccine in their country men  and women  from the US got fewer
questions correct. These questions are not directly comparable so
differences should be interpreted with caution, however there are
several explanations for why knowledge about vaccine availability
may  be poor in the US. Firstly, as availability of the vaccine varies by
state, this information is unlikely to publicised on a national level
and actively searching for vaccine availability information is likely
to be necessary. Secondly, while pharmaceutical advertisements
seem to have helped raise awareness of HPV in the US, even those
who recall having seen DTC HPV adverts found it hard to under-
stand and recall what they had seen [25] and not surprisingly those
who used advertisements as their only source of information about
HPV had lower knowledge than those who  sought additional infor-
mation [26]. While fewer men  and women have heard of HPV in
the UK and Australia, those who have may  feasibly be those who
the vaccine is most applicable to and therefore know more about
its availability.
There are a number of limitations to this study. The recruitment
of online panel samples and the use of quotas to ensure ade-
quate representation of different age-groups and genders means
our sample may  not be representative of the US, UK and Australian
populations. Although the vast majority of the population seem
to have some access to the internet [27], there are still inequal-
ities and those who opt in to internet survey panels may  not be
representative of those with internet access due to self-selection
bias. HPV knowledge is also higher in those who use the internet
[16]. Having said that, the aim of this survey was  to compare HPV
knowledge across three countries and online recruitment allowed
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or directly comparable recruitment methods. There is no reason
o suppose that recruitment biases would have differed systemati-
ally between the three countries. It is difﬁcult to report an accurate
esponse rate for online surveys. Of those who were directed to our
urvey and eligible to take part 62% completed the survey, but this
enominator does not represent those who decided not to click
n the survey link in the email. The study measured knowledge
sing closed questions which we know from previous work is likely
o give higher estimates of knowledge than a more open-ended
pproach [12,28].  However we chose to use a validated measure
hat is easy to administer and code, for pragmatic reasons and to
acilitate comparison with future studies.
This study explores differences in HPV knowledge and aware-
ess between three countries that have introduced HPV vaccination
n the last ﬁve years. Awareness seems to be high in all three
ountries although inequalities still exist, with lower awareness
mong those with lower educational level. We  have highlighted
ome signiﬁcant gaps in HPV knowledge which should be the tar-
et of future information campaigns. Poor knowledge in men  may
ose a particular challenge as and when HPV vaccination for males
ecomes available.
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